Physician profile
Dave Fields
NPI 1598423964
$5,536.13
in general payments reported to CMS, 2019-2025
16 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $723 · 2023: $2,209 · 2024: $1,171 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,796 · Education: $16.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,796.18 |
| Education | $16.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,617.84 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $921.58 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $568.64 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $501.24 | 2023-2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $425.18 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Indivior INC. | $400.12 | 2023-2025 | Perseris, Sublocade |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $341.09 | 2025 | Abilify Asimtufii, Rejoyn |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $264.84 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $155.96 | 2022-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $108.60 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $59.62 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $58.29 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $50.60 | 2022-2025 | Trintellix, Vyvanse |
| Sunovion Pharmaceuticals INC. | $29.28 | 2022 | |
| Lundbeck LLC | $19.64 | 2025 | Rexulti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $13.61 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dave Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.